Filing Details
- Accession Number:
- 0000914190-19-000460
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-06 16:50:56
- Reporting Period:
- 2019-12-04
- Accepted Time:
- 2019-12-06 16:50:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197788 | J Harold Wiens | 614 Mckinley Place Ne Minneapolis MN 55413 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-04 | 2,000 | $87.83 | 7,221 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-04 | 485 | $216.47 | 6,736 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-04 | 514 | $217.29 | 6,222 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-04 | 921 | $218.75 | 5,301 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-04 | 80 | $219.31 | 5,221 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-12-04 | 2,000 | $0.00 | 2,000 | $87.83 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2014-05-15 | 2024-05-15 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | $91.78 | 2014-10-30 | 2024-10-30 | 4,000 | 4,000 | Direct |
| Common Stock | Stock Option (right to buy) | $87.34 | 2016-10-29 | 2025-10-28 | 4,260 | 4,260 | Direct |
| Common Stock | Stock Option (right to buy) | $101.19 | 2017-10-26 | 2026-10-26 | 3,985 | 3,985 | Direct |
| Common Stock | Stock Option (right to buy) | $125.05 | 2018-10-25 | 2027-10-26 | 3,125 | 3,125 | Direct |
| Common Stock | Stock Option (right to buy) | $179.84 | 2019-10-24 | 2028-10-25 | 1,898 | 1,898 | Direct |
| Common Stock | Stock Option (right to buy) | $201.64 | 2029-10-24 | 2,011 | 2,011 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-10-30 | 4,000 | 4,000 | Direct |
| 2025-10-28 | 4,260 | 4,260 | Direct |
| 2026-10-26 | 3,985 | 3,985 | Direct |
| 2027-10-26 | 3,125 | 3,125 | Direct |
| 2028-10-25 | 1,898 | 1,898 | Direct |
| 2029-10-24 | 2,011 | 2,011 | Direct |
Footnotes
- The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
